Theory Paper IIIDrNB Cardiology – Theory Notes
CONTRAST-ASSOCIATED ACUTE KIDNEY INJURY (CA-AKI) / CIN
IDEFINITION AND NOMENCLATURE SHIFT
- Nomenclature Update: Contemporary guidelines (ACC/ESC/KDIGO) have shifted terminology from Contrast-Induced Nephropathy (CIN) to Contrast-Associated Acute Kidney Injury (CA-AKI), recognizing that contrast media is often a contributing factor alongside hemodynamic instability, atheroembolism, and nephrotoxic drugs rather than the sole cause in hospitalized cardiac patients.
- Diagnostic Definition (KDIGO): An absolute increase in serum creatinine by 0.3 mg/dL or greater (within 48 hours), or a relative increase of 25 percent or greater (or 1.5-fold per KDIGO) from baseline, occurring within 48 to 72 hours after intravascular administration of iodinated contrast media.
- Clinical Implications: Development of CA-AKI increases short- and long-term all-cause mortality, accelerates progression to End-Stage Renal Disease (ESRD), prolongs hospital length of stay, and increases 1-year Major Adverse Cardiovascular Events (MACE).
IICORE DUAL-HIT PATHOPHYSIOLOGY
- Medullary Ischemia (The Hemodynamic Hit): Iodinated contrast media induces a transient initial vasodilation followed by intense, prolonged intrarenal vasoconstriction (mediated by endothelin and adenosine release combined with nitric oxide and prostaglandin depletion); the renal outer medulla, which physiologically operates at low oxygen tension, suffers acute ischemic tubular injury.
- Direct Tubular Cytotoxicity (The Cellular Hit): Filtered contrast molecules become concentrated within the renal tubules, increasing tubular fluid viscosity, generating Reactive Oxygen Species (ROS), and exerting direct osmotic cytotoxicity that triggers tubular epithelial cell apoptosis and cast obstruction.
IIIPRE-PROCEDURAL RISK STRATIFICATION (THE MEHRAN SCORE)
- The Mehran Risk Score (Pre-Procedural Risk Tool): Quantifies baseline CA-AKI risk using eight clinical and procedural variables: Hypotension, Intra-Aortic Balloon Pump (IABP) use, Congestive Heart Failure, Age greater than 75 years, Anemia, Diabetes Mellitus, Contrast Media Volume, and baseline eGFR / Serum Creatinine.
- Vulnerability Thresholds: A baseline eGFR less than 60 mL/min/1.73 m2 identifies the at-risk cohort, while an eGFR less than 30 mL/min/1.73 m2 denotes extreme risk.
IVPREVENTIVE STRATEGIES (THE NEPHROPROTECTION ALGORITHM)
AIntravascular Volume Expansion (The Gold Standard — Class I)
- Standard Hydration Protocol: Administer intravenous isotonic saline (0.9% NaCl) at 1.0 to 1.5 mL/kg/hour starting 12 hours before and continuing for 24 hours after the procedure.
- Physiological Rationale: Expands intravascular volume, suppresses vasopressin and RAAS activation, dilutes intratubular contrast concentration, and accelerates tubular transit.
BContrast Volume Minimization and Intravascular Imaging
- The Contrast-to-eGFR Ratio: Keep total Contrast Volume (in mL) to eGFR ratio strictly less than 3.0 (and less than 2.0 in severe CKD).
- Contrast Selection: Use Low-Osmolar Contrast Media (LOCM) or Iso-Osmolar Contrast Media (IOCM — Iodixanol); high-osmolar contrast media are contraindicated.
- Imaging-Guided PCI: Utilize IVUS or OCT for vessel sizing and stent optimization to minimize or eliminate angiographic contrast injections.
CPharmacological Optimization
- High-Dose Statin Pre-Loading (Class IIa): Pre-procedural loading with high-intensity Rosuvastatin or Atorvastatin reduces CA-AKI incidence via pleiotropic antioxidant, anti-inflammatory, and endothelial-protective effects.
- Withholding Nephrotoxins and the Metformin Rule: Discontinue NSAIDs and aminoglycosides 24 to 48 hours prior to contrast exposure. Metformin is withheld at the time of the procedure and for 48 hours post-procedure (restarting once renal function is confirmed stable) strictly to prevent metformin-associated lactic acidosis should CA-AKI occur, as Metformin itself is not nephrotoxic.
DIneffective Interventions (Class III — No Benefit or Harm)
- Oral or Intravenous N-Acetylcysteine (NAC): Provides zero renoprotective benefit.
- Intravenous Sodium Bicarbonate: Not superior to isotonic normal saline.
- Prophylactic Hemodialysis: Does not prevent CA-AKI (Class III); prophylactic hemofiltration may be considered only in selected severe CKD before complex PCI (Class IIb).
| Landmark Trial | Intervention Evaluated | Key Clinical Outcome & Practice Impact |
|---|---|---|
| PRESERVE Trial | 2x2 Factorial: IV Sodium Bicarbonate vs. IV 0.9% Saline & Oral NAC vs. Placebo | No benefit of Sodium Bicarbonate over Normal Saline, and zero benefit of N-Acetylcysteine; confirmed Isotonic Saline as the gold standard |
| POSEIDON Trial | LVEDP-Guided Isotonic Saline Hydration vs. Standard Fixed Hydration | Tailoring IV fluid rate to cath-lab LVEDP significantly reduced CA-AKI without precipitating pulmonary edema |
| REMEDIAL III Trial | Urine-Flow-Rate-Guided Hydration (RenalGuard) vs. LVEDP-Guided Hydration | Furosemide-induced high urine output (>300 mL/h) matched with automated IV saline replacement further reduced CA-AKI in very-high-risk patients |
VMANAGEMENT OF ESTABLISHED CA-AKI
- Supportive Hemodynamic and Metabolic Care: Strict intake/output charting, daily serum creatinine and electrolyte monitoring, maintenance of euvolemia, and correction of hyperkalemia and metabolic acidosis.
- Indications for Urgent Renal Replacement Therapy (Hemodialysis — “AEIOU”): Reserved strictly for refractory Acidosis, Electrolyte derangement (hyperkalemia), Intoxication, Volume Overload (diuretic-refractory pulmonary edema), or Uremic complications (pericarditis or encephalopathy).
Key references
- Weisbord SD, Gallagher M, Jneid H, et al. (PRESERVE Trial Investigators): Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine, New England Journal of Medicine.
- Brar SS, Aharonian V, Mansukhani P, et al. (POSEIDON Investigators): Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial, The Lancet.
- Mehran R, Dangas GD, Weisbord SD: Contrast-Associated Acute Kidney Injury, New England Journal of Medicine.
meritmedscript.comDr. Sidhartha Mullapudi
